Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes

Zhu, Wuyun; Tanday, Neil; Flatt, Peter; Irwin, Nigel

doi:10.1016/j.peptides.2022.170923

Cited by 17 publications

(8 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have reported that the XCL1 [182], HLA-DMB [183], CD40 [184], HLA-DRA [185], RUNX1 [186], IL18R1 [187], NINJ2 [188], ACE (angiotensin I converting enzyme) [189], CD44 [190], IL4R [191], MYD88 [192], WNT9B [193], CXCL16 [194], CXCL13 [195], RORB (RAR related orphan receptor B) [196], GDF15 [197], THEMIS (thymocyte selection associated) [198], KCNH7 [199], BTK (Bruton tyrosine kinase) [200] and MOBP (myelin associated oligodendrocyte basic protein) [201] are a key regulators of multiple sclerosis. Recently, increasing evidence demonstrated that HLA-DMB [202], VIP (vasoactive intestinal peptide) [203], GATA6 [204], CD40 [205], TFAP2B [206], HFE (homeostatic iron regulator) [207], IGFBP7 [208], NPY2R [209], CCL2 [210], AQP5 [211], HLA-DMA [212], RUNX1 [81], PPY (pancreatic polypeptide) [213], ASPA (aspartoacylase) [214], NOS1 [215], ADAM12 [216], NPPC (natriuretic peptide C) [217], COL1A1 [218], IL1R1 [219], ABCG2 [220], ACE (angiotensin I converting enzyme) [221], CD34 [222], HLA-DPA1 [223], A2M [224], MEOX2 [225], CDKN2A [226], SERPINE1 [227], CD44 [228], FABP4 [108], ITGB3 [229], ALOX5AP [230], SFRP4 [231], ISM1 [232], IL4R [233], RUNX2 [234], CASP1 [235], CCR4 [236], MYD88 [237], DRD3 [238], STAT6 [239], ANXA1 [240], CAV1 [241], RGS4 [242], SPHK1 [243], CYP2C8 [244], CD163 [245], DIRAS3 [131], POSTN (periostin) [246], SELL (selectin L) [247], TMPRSS2 [248], CXCL16 […”

Section: Discussionmentioning

confidence: 99%

“…VIP (vasoactive intestinal peptide) [388], CD40 [389], WT1 [390], HFE (homeostatic iron regulator) [391], TAC1 [392], AQP5 [393], WNT2B [394], RUNX1 [395], NOS1 [396], DKK2 [339], ADAM12 [397], ABCG2 [398], NINJ2 [399], ACE (angiotensin I converting enzyme) [400], PRKCB (protein kinase C beta) [401], A2M [365], MEOX2 [402], CDKN2A [403], PLXNA4 [404], SPINT1 [405], SERPINE1 [406], RGCC (regulator of cell cycle) [407], CD44 [408], CASP1 [409], MYD88 [410], DRD3 [411], UNC5C [412], LOX (lysyl oxidase) [413], SPHK1 [414], RPH3A [415], CXCL16 [416], CASS4 [417], IFITM3 [418], COL25A1 [419], SPARCL1 [420], FOXG1 [421], CHRM1 [422], HSPA2 [423], HGF (hepatocyte growth factor) [424], IL33 [425], MEG3 [426], RSPO2 [427], PCSK9 [428], PCSK9 [429], RORB (RAR related orphan receptor B) [430], ANGPT4 [431], CDH13 [432], PCP4 [433], ANG (angiogenin) [434], GDF15 [435], OPRD1 [436], PDE11A [437], TREML1 [438], GP6 [439], BTK (Bruton tyrosine kinase) [440], DSC1 [441], LAMP5 [442] and ADH1B [443] were identified to be associated with Alzheimer’s disease. VIP (vasoactive intestinal peptide) [444], CD40 [445], TFAP2B [446], NPY2R [447], CCL2 [448], COL1A2 [80], RUNX1 [449], PPY (pancreatic polypeptide) [213], ASPA (aspartoacylase) [214], TBX15 [450], ADAM12 [451], NPPC (natriuretic peptide C) [88], COL1A1 [89], ABCG2 [452], STING1 […”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Screening of the Key Genes and Signaling Pathways for Schizophrenia Using Bioinformatics and Next Generation Sequencing Data Analysis

Vastrad,

Vastrad

2023

Preprint

View full text Add to dashboard Cite

Schizophrenia is thought to be the most prevalent chronic psychiatric disorder. Numerous proteins have been identified that are associated with the occurrence and development of schizophrenia. This study aimed to identify potential core genes and pathways involved in schizophrenia, through exhaustive bioinformatic and next generation sequencing (NGS) data analyses using GSE20966 NGS data of neural progenitor cells and neurons obtained from healthy controls and patients with schizophrenia. The NGS data were downloaded from the Gene Expression Omnibus database. NGS data was processed by the DESeq2 package in R software and the differentially expressed genes (DEGs) were identified. Gene Ontology (GO) enrichment analysis and REACTOME pathway enrichment analysis were carried out to identify potential biological functions and pathways of the DEGs. Protein-protein interaction (PPI) network, module, miRNA-hub gene regulatory network and TF-hub gene regulatory network analysis were performed to identify the hub genes, miRNA and TFs. Potential hub genes were analyzed using receiver operating characteristic (ROC) curves in the R package (pROC). In this investigation, an overall 955 DEGs were identified: 478 genes were remarkably up regulated and 477 genes were distinctly down regulated. These genes were enriched for GO terms and pathways mainly involved in the multicellular organismal process, GPCR ligand binding, regulation of cellular process and amine ligand-binding receptors. MYC, FN1, CDKN2A, EEF1G, CAV1, ONECUT1, SYK, MAPK13, TFAP2A and BTK were considered the potential hub genes. miRNA-hub gene regulatory network and TF-hub gene regulatory network were constructed successfully. On the whole, the findings of this investigation enhance our understanding of the potential molecular mechanisms of schizophrenia and provide potential targets for further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Screening of the Key Genes and Signaling Pathways for Schizophrenia Using Bioinformatics and Next Generation Sequencing Data Analysis

Vastrad,

Vastrad

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…This results in reduced food intake and slowed weight gain. 15 The effects of OXM are to reduce gastric secretion and food intake when administered centrally to rodents or peripherally to rodents/humans. No separate receptor has been identified for OXM.…”

Section: Brain-gut Axismentioning

confidence: 99%

Obesity and Gastrointestinal Regulation of Food Intake

Demirtaş,

Sümer

2024

Farabi Tıp Dergisi

View full text Add to dashboard Cite

ABSTRACT Objective: The aim is to explain the role of the gastrointestinal system in obesity and related complications by focusing on the biological mechanisms between obesity and the gastrointestinal system, based on the latest evidence in the literature. Methods: A systematic search of the literature in the PubMed and ScienceDirect databases was conducted. Results: Factors such as inflammation, mechanical space-occupying effect, microbiota, adipocyte peptides are involved in the development of obesity-related gastrointestinal system comorbidities. However, obesity occurs when the connection between the gastrointestinal tract and the brain changes. Signaling dysfunction disrupts the brain-gut axis, leading to increased frequency of food intake and excessive fat accumulation. Conclusion: Obesity increases the risk of developing gastrointestinal system disorders. However, the gastrointestinal tract and its pathophysiology play a key role in the regulation of food intake and subsequent progression to obesity.

show abstract

“…The endocrine pancreas secretes pancreatic polypeptide (PP), a hormone involved in the gut–hypothalamic axis control of satiety and appetite [ 34 ]. It exhibits a selective affinity for Y4R [ 12 ].…”

Section: The Neuropeptide Y System: Peptides and Receptorsmentioning

confidence: 99%

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies

Sánchez

Rodríguez

Coveñas

2023

IJMS

View full text Add to dashboard Cite

Currently available data on the involvement of neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) and their receptors (YRs) in cancer are updated. The structure and dynamics of YRs and their intracellular signaling pathways are also studied. The roles played by these peptides in 22 different cancer types are reviewed (e.g., breast cancer, colorectal cancer, Ewing sarcoma, liver cancer, melanoma, neuroblastoma, pancreatic cancer, pheochromocytoma, and prostate cancer). YRs could be used as cancer diagnostic markers and therapeutic targets. A high Y1R expression has been correlated with lymph node metastasis, advanced stages, and perineural invasion; an increased Y5R expression with survival and tumor growth; and a high serum NPY level with relapse, metastasis, and poor survival. YRs mediate tumor cell proliferation, migration, invasion, metastasis, and angiogenesis; YR antagonists block the previous actions and promote the death of cancer cells. NPY favors tumor cell growth, migration, and metastasis and promotes angiogenesis in some tumors (e.g., breast cancer, colorectal cancer, neuroblastoma, pancreatic cancer), whereas in others it exerts an antitumor effect (e.g., cholangiocarcinoma, Ewing sarcoma, liver cancer). PYY or its fragments block tumor cell growth, migration, and invasion in breast, colorectal, esophageal, liver, pancreatic, and prostate cancer. Current data show the peptidergic system’s high potential for cancer diagnosis, treatment, and support using Y2R/Y5R antagonists and NPY or PYY agonists as promising antitumor therapeutic strategies. Some important research lines to be developed in the future will also be suggested.

show abstract

Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes

Cited by 17 publications

References 103 publications

Screening of the Key Genes and Signaling Pathways for Schizophrenia Using Bioinformatics and Next Generation Sequencing Data Analysis

Screening of the Key Genes and Signaling Pathways for Schizophrenia Using Bioinformatics and Next Generation Sequencing Data Analysis

Obesity and Gastrointestinal Regulation of Food Intake

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies

Contact Info

Product

Resources

About